Skip to main content
Fig. 3 | Biology Direct

Fig. 3

From: MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression

Fig. 3

MAP7D3 depletion significantly sensitizes TNBC cells to docetaxel/gemcitabine treatment and reduces breast cancer initiating cells (BCICs)-associated protein marker expression. (A) Determination of the IC50 of docetaxel in the control IV2 cells and the shMAP7D3 IV2 cells. (B) Statistical analysis of the IC50 of docetaxel between the control IV2 cells and the shMAP7D3 IV2 cells. P < 0.05. (C) Determination of the IC50 of gemcitabine in the control IV2 cells and the shMAP7D3 IV2 cells (D) Statistical analysis of the IC50 of docetaxel between the control IV2 cells and the shMAP7D3 IV2 cells. P < 0.05. (E) Determination of the IC50 of docetaxel in the control 468-LN cells and the shMAP7D3 468-LN cells. (F) Statistical analysis of the IC50 of docetaxel between the control 468-LN cells and the shMAP7D3 468-LN cells. P < 0.05. (G) Determination of the IC50 of gemcitabine in the control 468-LN cells and the shMAP7D3 468-LN cells. (H) Statistical analysis of the IC50 of gemcitabine between the control 468-LN cells and the shMAP7D3 468-LN cells. P < 0.05. (I) Western blotting analysis of breast cancer initiating cells (BCICs) protein marker expressions in the control cells and shMAP7D3 cells. (J) Western blotting analysis of GTP-Rac1 pull-down in the control cells and shMAP7D3 cells. Each in vitro experiment was performed in triplicate and repeated three times

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us